心房颤动筛查:美国预防服务工作组更新版证据报告与系统综述
本系统综述纳入26项研究(N=113 784),评估无卒中成人房颤筛查的证据。筛查可检出更多未诊断房颤,但对健康结局影响证据有限;抗凝治疗与较低首发卒中及死亡风险相关,但大出血风险估计不精确;尚无试验评估筛查检出人群抗凝的获益与危害。
要点
- 间歇或连续心电图筛查较不筛查可检出更多房颤,风险差范围1.0%-4.8%。
- 华法林较安慰剂与较低缺血性卒中(汇总RR 0.32)和全因死亡(汇总RR 0.68)相关。
- 华法林大出血汇总RR 1.8(95%CI 0.85-3.7),直接口服抗凝药大出血调整OR 1.38-2.21,CI未排除无效。
核心结论
- 筛查可检出更多未知房颤,但对健康结局影响的证据有限。
- 抗凝与较低首发卒中和死亡风险相关,但大出血风险增加且估计不精确;尚无试验评估筛查检出人群抗凝的获益与危害。
研究设计与样本
- 系统综述纳入26项研究(N=113 784),检索PubMed、Cochrane Library和试验注册库至2020年10月5日,文献监测至2021年10月31日。
- 纳入无症状且无已知房颤或既往卒中者的筛查随机临床试验、检测准确性研究、房颤患者抗凝随机临床试验、系统综述及报告危害的观察性研究。
- 由两名评价者评估题目/摘要、全文和研究质量并提取数据;至少3项相似研究时进行Meta分析。
主要发现
- 1项每日两次心电图筛查2周的随机临床试验(n=28 768)中,筛查组6.9年复合终点(缺血性卒中、出血性卒中、系统性栓塞、全因死亡和出血住院)可能性较低(HR 0.96,95%CI 0.92-1.00;P=0.045),但该研究有诸多局限性。
- 4项随机临床试验(n=32 491)中,间歇和连续心电图筛查较不筛查检出显著更多房颤(风险差范围1.0%-4.8%)。
- 临床主要为持续性房颤人群中,华法林治疗平均1.5年较安慰剂与较少缺血性卒中(汇总RR 0.32,95%CI 0.20-0.51;5项随机临床试验;n=2415)和较低全因死亡(汇总RR 0.68,95%CI 0.50-0.93)相关。
- 与安慰剂间接比较中,直接口服抗凝药与较低卒中发生率相关(调整OR范围0.32-0.44)。
- 华法林较安慰剂的大出血汇总RR为1.8(95%CI 0.85-3.7;5项随机临床试验;n=2415);直接口服抗凝药较安慰剂或不治疗的大出血调整OR范围为1.38-2.21,但CI未排除无效。
关键数值与推荐
- 间歇和连续心电图筛查较不筛查检出更多房颤的风险差范围为1.0%-4.8%。
- 华法林较安慰剂缺血性卒中汇总RR 0.32(95%CI 0.20-0.51),全因死亡汇总RR 0.68(95%CI 0.50-0.93)。
- 华法林较安慰剂大出血汇总RR 1.8(95%CI 0.85-3.7)。
- 直接口服抗凝药较安慰剂卒中调整OR范围0.32-0.44,大出血调整OR范围1.38-2.21。
临床怎么用
- 原文未据此给出推荐。
局限性
- 1项每日两次心电图筛查2周的随机临床试验(n=28 768)有诸多局限性。
- 关于筛查对健康结局影响的证据有限。
- 大出血危害的估计不精确,置信区间未排除无效。
- 尚无试验评估筛查检出人群抗凝的获益与危害。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation (AF), the most common arrhythmia, increases the risk of stroke. OBJECTIVE: To review the evidence on screening for AF in adults without prior stroke to inform the US Preventive Services Task Force. DATA SOURCES: PubMed, Cochrane Library, and trial registries through October 5, 2020; references, experts, and literature surveillance through October 31, 2021. STUDY SELECTION: Randomized clinical trials (RCTs) of screening among asymptomatic persons without known AF or prior stroke; test accuracy studies; RCTs of anticoagulation among persons with AF; systematic reviews; and observational studies reporting harms. DATA EXTRACTION AND SYNTHESIS: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted. MAIN OUTCOMES AND MEASURES: Detection of undiagnosed AF, test accuracy, mortality, stroke, stroke-related morbidity, and harms. RESULTS: Twenty-six studies (N = 113 784) were included. In 1 RCT (n = 28 768) of twice-daily electrocardiography (ECG) screening for 2 weeks, the likelihood of a composite end point (ischemic stroke, hemorrhagic stroke, systemic embolism, all-cause mortality, and hospitalization for bleeding) was lower in the screened group over 6.9 years (hazard ratio, 0.96 [95% CI, 0.92-1.00]; P = .045), but that study had numerous limitations. In 4 RCTs (n = 32 491), significantly more AF was detected with intermittent and continuous ECG screening compared with no screening (risk difference range, 1.0%-4.8%). Treatment with warfarin over a mean of 1.5 years in populations with clinical, mostly persistent AF was associated with fewer ischemic strokes (pooled risk ratio [RR], 0.32 [95% CI, 0.20-0.51]; 5 RCTs; n = 2415) and lower all-cause mortality (pooled RR, 0.68 [95% CI, 0.50-0.93]) compared with placebo. Treatment with direct oral anticoagulants was also associated with lower incidence of stroke (adjusted odds ratios range, 0.32-0.44) in indirect comparisons with placebo. The pooled RR for major bleeding for warfarin compared with placebo was 1.8 (95% CI, 0.85-3.7; 5 RCTs; n = 2415), and the adjusted odds ratio for major bleeding for direct oral anticoagulants compared with placebo or no treatment ranged from 1.38 to 2.21, but CIs did not exclude a null effect. CONCLUSIONS AND RELEVANCE: Although screening can detect more cases of unknown AF, evidence regarding effects on health outcomes is limited. Anticoagulation was associated with lower risk of first stroke and mortality but with increased risk of major bleeding, although estimates for this harm are imprecise; no trials assessed benefits and harms of anticoagulation among screen-detected populations.
引用
- Kahwati LC, Asher GN, Kadro ZO, et al. Screening for Atrial Fibrillation: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35076660. doi:10.1001/jama.2021.21811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。